Articles by Rita Peters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rita Peters

Defining Quality Metrics is No Easy Task

ISPE and PDA take on the challenge of recommending quality metrics.
Feb 2, 2014

ISPE and PDA take on the challenge of recommending quality metrics.

2014 Manufacturing Trends and Outlook

Single-use systems and other technologies drive process efficiencies, but there is room for improvement.
Jan 15, 2014

A survey of BioPharm International readers found that single-use systems and other technologies are driving process efficiencies in biomanufacturing, but there is room for improvement.

New Dynamics in Drug Pricing and Prescribing

Jan 3, 2014

Generics, market dynamics, and global demand are changing drug-spending patterns.

Drugs At What Cost

Jan 2, 2014

Generics, market dynamics, and global demand are changing drug spending patterns.

Industry Optimism Outweighs Personal Job Security

Restructuring mutes employment optimism.
Dec 2, 2013

Pharmaceutical Technology's 2013 Employment Survey reveals some optimism for the industry's future performance, but ongoing concerns about individual job prospects.

Uncertainty in the Workplace

Industry mergers, acquisitions and downsizing contribute to uncertainty in job security.
Dec 2, 2013

Industry mergers, acquisitions and downsizing contribute to uncertainty in job security in the European bio/pharmaceutical market.

New Funding and Approval Pathways Prove Popular

The JOBS Act and FDASIA show early signs of accelerating drug development.
Nov 2, 2013

The JOBS Act and FDASIA show early signs of accelerating drug development.

Filling a Gap in Drug Safety

As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.
Aug 2, 2013

As the Supreme Court ruled on generic-drug liability, FDA outlined new rules for warning labels.

The Pains of Change

Pharma and biotech companies, with the rest of the health care industry, must face change.
Jul 2, 2013

Pharma and biotech companies, with the rest of the health care industry, must face change.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here